Adult patients with severe allergic asthma and COPD who received omalizumab (Xolair) showed improvements in asthma control and health-related quality of life, according to an Australian study.

In the registry-based study, treatment with omalizumab improved both outcomes in all 177 patients assessed, researchers reported.

Specifically, asthma control and health related quality of life (HRQoL) significantly improved in patients with severe allergic asthma and doctor diagnosed COPD — Asthma Control Questionnaire (ACQ-5) scores at baseline improved from 3.68 to 1.69 post-omalizumab treatment (P<0.0001), while scores on the Asthma Quality of Life Questionnaire (AQLQ) improved from 4.03 to 5.56 (P<0.016).